290 related articles for article (PubMed ID: 21248621)
1. Targeting the proteasome with bortezomib in multiple myeloma: update on therapeutic benefit as an upfront single agent, induction regimen for stem-cell transplantation and as maintenance therapy.
Driscoll JJ; Burris J; Annunziata CM
Am J Ther; 2012 Mar; 19(2):133-44. PubMed ID: 21248621
[TBL] [Abstract][Full Text] [Related]
2. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
3. Update on the proteasome inhibitor bortezomib in hematologic malignancies.
Goy A; Gilles F
Clin Lymphoma; 2004 Mar; 4(4):230-7. PubMed ID: 15072615
[TBL] [Abstract][Full Text] [Related]
4. Carfilzomib: a novel second-generation proteasome inhibitor.
Khan ML; Stewart AK
Future Oncol; 2011 May; 7(5):607-12. PubMed ID: 21568676
[TBL] [Abstract][Full Text] [Related]
5. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
6. Frontline treatment of multiple myeloma.
Fonseca R
Hematology; 2012 Apr; 17 Suppl 1():S101-4. PubMed ID: 22507793
[TBL] [Abstract][Full Text] [Related]
7. Dissecting bortezomib: development, application, adverse effects and future direction.
Cao B; Li J; Mao X
Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies.
Jackson G; Einsele H; Moreau P; Miguel JS
Cancer Treat Rev; 2005 Dec; 31(8):591-602. PubMed ID: 16298074
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition in the treatment of cancer.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Cell Cycle; 2005 Feb; 4(2):290-6. PubMed ID: 15655370
[TBL] [Abstract][Full Text] [Related]
10. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
Caravita T; de Fabritiis P; Palumbo A; Amadori S; Boccadoro M
Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib in multiple myeloma.
Mateos MV; San Miguel JF
Best Pract Res Clin Haematol; 2007 Dec; 20(4):701-15. PubMed ID: 18070714
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib for previously untreated multiple myeloma.
Delforge M
Expert Opin Pharmacother; 2011 Nov; 12(16):2553-64. PubMed ID: 21942881
[TBL] [Abstract][Full Text] [Related]
14. New developments with bortezomib in treating multiple myeloma.
Reddy GK
Clin Lymphoma; 2004 Mar; 4(4):215-6. PubMed ID: 15072611
[No Abstract] [Full Text] [Related]
15. Emerging trends in the clinical use of bortezomib in multiple myeloma.
Richardson PG; Schlossman R; Mitsiades C; Hideshima T; Munshi N; Anderson K
Clin Lymphoma Myeloma; 2005 Sep; 6(2):84-8. PubMed ID: 16231845
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibitor, bortezomib, for myeloma and lymphoma.
Tobinai K
Int J Clin Oncol; 2007 Oct; 12(5):318-26. PubMed ID: 17929113
[TBL] [Abstract][Full Text] [Related]
17. The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
Armand JP; Burnett AK; Drach J; Harousseau JL; Löwenberg B; San Miguel J
Oncologist; 2007 Mar; 12(3):281-90. PubMed ID: 17405892
[TBL] [Abstract][Full Text] [Related]
18. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
Neben K; Lokhorst HM; Jauch A; Bertsch U; Hielscher T; van der Holt B; Salwender H; Blau IW; Weisel K; Pfreundschuh M; Scheid C; Dührsen U; Lindemann W; Schmidt-Wolf IG; Peter N; Teschendorf C; Martin H; Haenel M; Derigs HG; Raab MS; Ho AD; van de Velde H; Hose D; Sonneveld P; Goldschmidt H
Blood; 2012 Jan; 119(4):940-8. PubMed ID: 22160383
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
Cavo M
Leukemia; 2006 Aug; 20(8):1341-52. PubMed ID: 16810203
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology, pharmacokinetics, and practical applications of bortezomib.
Schwartz R; Davidson T
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):14-21. PubMed ID: 15688598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
